Dutch LSH Firms Eye Collaboration in US Amid Policy Shifts
The Hague, Thursday, 3 April 2025.
A USA expert session will explore collaboration opportunities between Dutch Life Sciences and Health companies and the US, focusing on policy changes under the Trump administration.
Strategic Market Access and Policy Navigation
The upcoming expert session, scheduled for May 7, 2025, in The Hague, comes at a crucial time for Dutch Life Sciences and Health (LSH) organizations seeking to expand their presence in the United States market. The event, organized by the European American Chamber of Commerce Netherlands, Netherlands Enterprise Agency (RVO), and Task Force Health Care, will specifically target companies operating in Digital Health, Health Tech, MedTech, Telemedicine, and Medical Devices sectors [1].
Market Opportunity Analysis
The United States continues to maintain its position as the world’s largest healthcare market, offering robust investment opportunities for innovative medical technologies. The market’s attractiveness is particularly significant for Dutch LSH organizations seeking research partnerships and innovation collaborations [1]. This strategic focus aligns with ongoing initiatives such as the SMM LSH USA programme, which provides structured support for Dutch companies navigating the American healthcare landscape [1].
Concurrent Industry Developments
The timing of this expert session coincides with significant activity in the US-Dutch healthcare collaboration sphere. For instance, a parallel innovation mission in regenerative medicine is taking place in Boston and Manchester from April 6-11, 2025, demonstrating the breadth of bilateral healthcare initiatives [2]. The Massachusetts-Netherlands partnership stands as a unique arrangement, being the only formalized agreement of its kind between Massachusetts and any foreign nation [2].
Practical Implementation
The expert session will be hosted at RVO Den Haag, Prinses Beatrixlaan 2, and is offered free of charge to participants [1]. While the detailed program is still under development [alert! ‘program details pending publication’], the session promises to deliver critical insights from policy and legal experts, alongside real-world case studies of Dutch companies successfully operating in the United States market [1].